from Dr. Byington
April 2018: TMC3 Initiative
Today continues to be an exciting day for the Texas A&M Health Science Center. In addition to our strengthened partnership with CHI St. Joseph Health, we are excited to expand our reach within the largest medical complex in the world, through the forward-thinking TMC3 initiative.
TMC3, an unprecedented research campus in the Texas Medical Center, will house thousands of national leaders in discovery and innovation that will pioneer therapies and devices to advance health care in Texas, across the nation, and around the globe. This campus will establish Houston as the Third Coast, international hub for biomedical research.
As one of four founding institutions, Texas A&M Health Science Center will work collaboratively to bring top-tier researchers from the private sector, as well as leading researchers from its founding institutions together in this groundbreaking project, expected to be complete in 2022.
For Texas A&M, this transformational endeavor offers us a platform for research and commercial pursuits in the Texas Medical Center. TMC3 will be an important resource for the training of our EnMed students and a platform for our EnHealth initiatives. Looking to the future, we envision Texas A&M scientists and students contributing to innovative collaborations in the area of advanced imaging, drug discovery, as well as manufacturing of both drugs and devices with industry, hospital systems and a multitude of other health care stakeholders.
For more than 30 years, Houston has been home to our Institute of Biosciences and Technology, a translational research institute with a translational focus, and today, the Texas A&M Health Science Center builds on that tradition and is honored to be a partner in the transformational endeavor that is TMC3.
I am filled with excitement for the collaborative research and impact Texas A&M will have on the future of health care. For more information on our TMC3 initiative visit Vital Record to learn more.
Carrie L. Byington, MD